| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
254,921 |
421,551 |
1,262,027 |
1,480,093 |
| Total Sell Value |
$16,747,919 |
$26,516,522 |
$74,515,877 |
$82,888,946 |
| Total People Sold |
8 |
9 |
12 |
12 |
| Total Sell Transactions |
23 |
40 |
87 |
90 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2024-02-29 |
4 |
D |
$67.67 |
$677,647 |
D/D |
(10,014) |
473,946 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2024-02-29 |
4 |
D |
$67.67 |
$79,377 |
D/D |
(1,173) |
60,231 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2024-02-29 |
4 |
D |
$67.67 |
$106,242 |
D/D |
(1,570) |
82,706 |
|
- |
|
| Mutz Christopher |
HEAD OF RARE DISEASE |
• – – |
2024-02-29 |
4 |
D |
$67.67 |
$86,279 |
D/D |
(1,275) |
92,387 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2024-02-29 |
4 |
D |
$67.67 |
$71,595 |
D/D |
(1,058) |
148,830 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2024-02-29 |
4 |
D |
$67.67 |
$129,520 |
D/D |
(1,914) |
189,715 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2024-02-29 |
4 |
D |
$67.67 |
$110,640 |
D/D |
(1,635) |
49,679 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2024-02-15 |
4 |
D |
$57.55 |
$71,592 |
D/D |
(1,244) |
84,276 |
|
- |
|
| Mutz Christopher |
HEAD OF RARE DISEASE |
• – – |
2024-02-15 |
4 |
D |
$57.55 |
$72,571 |
D/D |
(1,261) |
93,662 |
|
- |
|
| Mutz Christopher |
HEAD OF RARE DISEASE |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
31,316 |
94,923 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,367 |
69,774 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
16,776 |
149,888 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,367 |
51,314 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
24,605 |
85,520 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
24,605 |
61,404 |
|
- |
|
| Davis Krista |
SVP, CHIEF HR OFFICER |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
20,131 |
52,718 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
35,790 |
191,629 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
134,216 |
483,960 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2024-02-13 |
4 |
AS |
$56.04 |
$14,010 |
D/D |
(250) |
36,799 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-23 |
4 |
AS |
$56.44 |
$846,600 |
I/I |
(15,000) |
882,620 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-22 |
4 |
AS |
$55.95 |
$318,467 |
I/I |
(5,692) |
897,620 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-19 |
4 |
AS |
$55.57 |
$251,399 |
I/I |
(4,524) |
903,312 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-18 |
4 |
AS |
$55.30 |
$541,055 |
I/I |
(9,784) |
907,836 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-17 |
4 |
AS |
$55.11 |
$551,100 |
I/I |
(10,000) |
917,620 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-16 |
4 |
AS |
$55.63 |
$278,150 |
I/I |
(5,000) |
927,620 |
|
- |
|
722 Records found
|
|
Page 3 of 29 |
|
|
0.14 (0.21%) 
